[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596674":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":33,"collaborators":7,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":7,"eligibilityCriteria":40,"healthyVolunteers":37,"sex":41,"minAge":7,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"St. Jude Children's Research Hospital","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Aimee Talleur, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","888-226-4343","referralinfo@stjude.org",[18],{"facility":5,"status":19,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"RECRUITING","Memphis","Tennessee","38105","United States","US",{"type":26,"coordinates":27},"Point",[28,29],-90.04898,35.14953,{"lat":29,"lon":28},[32],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100596674","car-t-cell-long-term-follow-up-quality-of-life-and-adverse-reactions-100596674",false,"NCT07048535","CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions","Inclusion Criteria:\n\n* ≤ 26-years old at the time of the first CAR treatment\n* Receipt of a CD19-containing CAR T-cell product (investigational or commercial) for B- ALL\n* Receipt of one unique CAR product (reinfusion of same product allowed)\n* Sustained remission without subsequent therapy post-CAR (exception= post-CAR consolidative HCT)\n* Receipt of only one prior HCT (inclusive of pre- or post-CAR)\n* ≥ 2-years post last CAR T-cell infusion\n\nExclusion Criteria:\n\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent","ALL",{"count":43,"type":44},80,"ESTIMATED","OBSERVATIONAL","To learn more about the long-term health in patients treated for B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Cluster of Differentiation antigen 19 (CD19)\n\n-redirected chimeric antigen receptor (CAR) T-cells.\n\nPrimary Objective:\n\nTo evaluate the feasibility of conducting standardized clinical assessments of pediatric, adolescent and young adult (AYA) B-ALL survivors post CD19-CAR T-cell therapy, treated at multiple institutions, leveraging the St Jude Lifetime Cohort (SJLIFE) clinical and research infrastructure.\n\nExploratory Objectives:\n\n* To describe the prevalence of persistent and new\u002Flate-onset health conditions developing ≥2-years post CD19-CAR T-cell therapy in survivors of pediatric and AYA B-ALL.\n* To characterize neurocognitive and neurologic function in survivors ≥2-years post CD19- CAR T-cell therapy.\n* To characterize immune health in survivors ≥2-years post CD19-CAR T-cell therapy.\n* To characterize functional status in survivors ≥2-years post CD19-CAR T-cell therapy.",[48],"B-Cell Acute Lymphoblastic Leukemia (B-ALL)",[50,51,52],"B-Cell Acute Lymphoblastic Leukemia","B-ALL","Survivorship","2026-04-23",{"date":55,"type":56},"2026-04-29","ACTUAL",{"date":58,"type":56},"2025-10-24",{"date":60,"type":44},"2029-07",{"name":5,"class":6},1]